Package Insert
Competition
Competition Continued
Rhopressa Studies
Rhopressa
100
Rhopressa indication
Rhopressa .02% is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
100
Which drug class is contraindicated for use in patients with overt cardiac failure
Beta Blockers
100
Blepharitis is an adverse reaction associated with which products
Simrinza, Azopt, Alphagan P
100
In the Rocket 2 study, which treatment provided the largest numeric reduction in IOP (up to 5.4 mmHG)
Rhopressa .02% BID
100
Rhopressa  is available in what dosage form and strength
Opthalmic solution containing .2 mg/ml of netarsudil
200
Name the contraindications of Rhopressa
NONE
200
IOP lowering for PGA's
25-35%
200
Eye Pruritis is typical adverse effect for
Alphagan, Combigan
200
In the phase 3 studies (Rocket 1, Rocket 2, and Rocket 4) what was the most prevalent ocular AE observed
Conjunctival hyperemia
200
Complete the sentence: As a rock inhibitor Rhopressa works at the cellular level in the TM to block the formation of stress fibers and 
increased trabecular outflow
300
How supplied, amount in bottle and size
2.5ml fill in a 4 ml container
300
IOP Lowering for Alpha agonist
18-25%
300
Name all of the PGA's (5 in total)
Xalatan, Lumigan, Travatan Z, Ziopan, Vyzulta
300
How long was 

Rocket 1

Rocket 2

Rocket 3

Studies

Rocket 1- 3 months

Rocket 2- 12 months

Rocket 3- 6 months

300
Rhopressa is thought to lower intraocular pressure primarily through its inhibition of 
Rho kinase
400
What do you do if you miss a dose
Advise patients that if one dose is missed, treatment should continue with the next dose in the evening
400
Latanoprost works to lower intraocular pressure via which mechanism
Increasing uveoscleral outlfow
400
What are the market advantages of Rhopressa
First Rho kinase inhibitor in the US, no contraindications
400
How many total patients were studied in Rocket 1, Rocket 2 and Rocket 4
Rocket 1- 411

Rocket 2- 756

Rocket 3- 708

Total-1875

400
Explain the efficacy of Rhopressa
Three clinical studies demonstrated up to 5 mmHG reductions in IOP in patients treated with Rhopressa .02% once daily in the evening
500
Name which adverse event has 53% and which 3 have approximately 20%
53%- conjunctival hyperemia

20%- corneal verticilata, instillation site pain, conjunctival hemorrhage

500
Dosing

PGA

CAI

Beta Blockers

Alpha Agonists

PGA-1

CAI- up to 4 times

Beta Blockers- 2

Alpha Agonists- 3

500
What products are competition with Rhopressa
All topical treatments that reduce IOP in OAH/OHT except for PGA's
500
In the Rocket 1 study, Rhopressa administration was associated with statistically significantly larger reductions in mean IOP in patients who were on a ________ prior to study entry compared with those who were not
PGA
500
Accurately describe corneal verticillata
It typically resolves after the medication causing it is discontinued.  It is rarely associated with reduction in visual acuity
M
e
n
u